Publications

BibTex format

@article{Ghanima:2020:10.1182/blood-2020-136651,
author = {Ghanima, W and Provan, D and Cooper, N and Matzdorff, A and Hou, M and Santoro, C and Morgan, M and Kruse, C and Zaja, F and Lahav, L and Tomiyama, Y and Winograd, M and Lovrencic, B and Bailey, T and Haenig, J and Bussel, JB},
doi = {10.1182/blood-2020-136651},
journal = {Blood},
pages = {2--3},
title = {ITP World Impact Survey (I-WISh) 2.0: Further Exploration of the Impact of ITP on Patients},
url = {http://dx.doi.org/10.1182/blood-2020-136651},
volume = {136},
year = {2020}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <jats:p>Immune thrombocytopenia (ITP) is an acquired autoimmune disorder defined by a platelet count &lt; 100 × 109/L without explanation, and an increased risk of bleeding. ITP itself as well as its treatments have multifaceted, often poorly understood impacts on patients' quality of life (QoL). These effects include impact on activities of daily living, emotional health, energy, ability to think well and clearly, and productivity in the workplace. There are limited data on which individual aspects of ITP are perceived both by patients and physicians as having the greatest impact on QoL. Understanding patients' perspectives is vital to optimize their QoL by specifying particular areas in need of therapy.</jats:p>               <jats:p>I-WISh 1.0 was an exploratory, cross-sectional survey in which 1507 patients with ITP and 472 physicians across 13 countries completed separate, but related, online surveys that included assessments of ITP signs and symptoms, impact of symptoms, and patient-physician relationships. These findings have been presented at previous ASH and EHA congresses, and manuscripts are currently in preparation. However, although I-WISh 1.0 provided considerable insights into unexplored facets of the effects of ITP, an all-too-large number of gaps in understanding still remain. In response to this, I-WISh 2.0 is currently being developed.</jats:p>               <jats:p>The objectives of the I-WISh 2.0 patient and physician cross-sectional surveys include: (1) to further explore the burden of fatigue and how it affects patients' lives, including what makes it better or worse; (2) to assess the emotional impact of living with chronic ITP, especially in relation to depression; (3) to assess how treatments for ITP can impact activities of daily living (positively and negatively); (4) to further relate effects of treatment to patients' QoL; and (5) to explore how telemedicine affects healthcare delivery for pati
AU  - Ghanima,W
AU  - Provan,D
AU  - Cooper,N
AU  - Matzdorff,A
AU  - Hou,M
AU  - Santoro,C
AU  - Morgan,M
AU  - Kruse,C
AU  - Zaja,F
AU  - Lahav,L
AU  - Tomiyama,Y
AU  - Winograd,M
AU  - Lovrencic,B
AU  - Bailey,T
AU  - Haenig,J
AU  - Bussel,JB
DO  - 10.1182/blood-2020-136651
EP  - 3
PY  - 2020///
SN  - 0006-4971
SP  - 2
TI  - ITP World Impact Survey (I-WISh) 2.0: Further Exploration of the Impact of ITP on Patients
T2  - Blood
UR  - http://dx.doi.org/10.1182/blood-2020-136651
VL  - 136
ER  -

Download

ProfessorNicholaCooper

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)